Biomarin Pharmaceutical Inc (BMRN)

Fixed asset turnover

		Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019
Revenue (ttm)	US$ in thousands	2,443,023	2,373,030	2,261,604	2,184,719	2,123,138	2,059,481	1,999,471	1,903,678	1,871,615	1,827,451	1,829,463	1,891,778	1,815,339	1,822,817	1,822,364	1,813,337	1,772,797	1,694,305	1,597,556	1,518,971
Property, plant and equipment	US$ in thousands	1,060,420	1,066,130	1,067,160	1,067,280	1,068,140	1,073,370	1,051,820	1,049,460	1,039,540	1,035,460	1,024,790	1,026,580	1,022,470	1,032,470	1,015,060	1,010,920	1,009,970	1,010,870	969,300	962,970
Fixed asset turnover		2.30	2.23	2.12	2.05	1.99	1.92	1.90	1.81	1.80	1.76	1.79	1.84	1.78	1.77	1.80	1.79	1.76	1.68	1.65	1.58

March 31, 2024 calculation

Fixed asset turnover = Revenue (ttm) ÷ Property, plant and equipment
= $2,443,023K ÷ $1,060,420K
= 2.30

The fixed asset turnover ratio measures how efficiently Biomarin Pharmaceutical Inc is generating revenue from its fixed assets. A higher ratio indicates that the company is utilizing its fixed assets effectively to generate sales.

The trend analysis of Biomarin's fixed asset turnover ratio shows a generally positive trend from 1.58 in Q2 2019 to 2.30 in Q1 2024, indicating improving efficiency in generating revenue from fixed assets over the period.

The company's fixed asset turnover ratio has shown fluctuations over the quarters but has mostly been increasing, reaching a peak of 2.30 in Q1 2024. This suggests that Biomarin has been able to increase its revenue generation from fixed assets over time.

Overall, Biomarin Pharmaceutical Inc's fixed asset turnover ratio reflects improving efficiency in utilizing fixed assets to generate revenue, which is a positive sign for the company's operational effectiveness.